Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Biosimilars Therapy
-
Abstract Number: 2796
A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis